Logistics Leaders - Specialty pharmaceuticals vs cell and gene therapy supply chain

The key difference in cell and gene therapy is that the patient is in the supply chain. Find out more from Sam Herbert, President of World Courier. 

VIDEO TRANSCRIPT:
 

The key difference in cell and gene therapy is the patient is in the supply chain. Traditional small and large molecules use bulk manufacturing, whereas in cell and gene therapy, we're often extracting cells from the patient, moving them through a customised manufacturing process, and then infusing them back into the patient. These patients are often very sick and often close to death, so it really requires us going through elaborate contingency planning and us designing a customised solution that meets our manufacturer's needs.